FORUM Pharmaceuticals Appoints Christine Boisclair As Vice President, Regulatory Affairs
7/9/2014 11:03:15 AM
WATERTOWN, Mass. – July 9, 2014 – FORUM Pharmaceuticals Inc. (previously known as EnVivo Pharmaceuticals, Inc.), a biotechnology company singularly focused on the development and delivery of innovative medicines to treat serious brain diseases, today announced the appointment of Christine Boisclair as Vice President, Regulatory Affairs. In this role, she will provide oversight for all aspects of the Company’s U.S. and international regulatory matters. Ms. Boisclair brings more than 20 years of regulatory affairs experience in the biotechnology and pharmaceutical industries to FORUM and will report to Dana C. Hilt, M.D., Senior Vice President Clinical Development and Chief Medical Officer.
“Encenicline, our lead investigational candidate in global Phase 3 clinical development, is actively enrolling patients in our schizophrenia and Alzheimer’s disease pivotal trials. We anticipate that Christine’s proven experience in delivering strategically successful regulatory filings for U.S. and European applications will prove valuable in our ongoing advancement of FORUM’s robust pipeline, particularly as we plan for an NDA submission for encenicline,” said Dr. Hilt. “We also welcome her strategic perspectives and guidance in progression of earlier-stage candidates in our portfolio, including FRM-0334, which is currently in development for genetically-targeted treatment of frontotemporal dementia.”
“I am excited to join the FORUM leadership team at this important juncture of the company’s growth, particularly with the Phase 3 development programs underway for encenicline in schizophrenia and Alzheimer’s disease,” said Ms. Boisclair. “So many lives are touched by serious brain diseases. It will be especially rewarding to contribute my regulatory skills to programs that can potentially bring new medicines that may improve the lives of these patients and their caregivers.”
Prior to FORUM, Ms. Boisclair most recently served as Vice President, Regulatory Affairs at Insmed Incorporated and as Senior Vice President, Global Regulatory Affairs at Agennix Inc. During her tenure at OSI Pharmaceuticals, Inc., she built the company’s regulatory affairs group, advancing in positions of increasing responsibility to Vice President, Regulatory Affairs. Ms. Boisclair’s prior positions include leadership roles at Genzyme Corporation, ImmuLogic Pharmaceutical Corporation and PAREXEL International Corporation. Earlier in her career, she worked at GD Searle & Co. Ltd. and Glaxo Group Research Ltd. Ms. Boisclair holds a Bachelor of Science Honors degree in biochemistry from York University, York, England.
About FORUM Pharmaceuticals Inc.
FORUM Pharmaceuticals Inc. and its subsidiaries (“FORUM Pharmaceuticals” or “FORUM”) are dedicated to developing groundbreaking medicines in support of all those who are affected by or caring for people with serious brain disease, to help them live fuller, more enriching lives. The Company’s robust and diverse pipeline is focused on discovering and developing new treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provide improvement in cognitive and overall function. FORUM’s lead compound, encenicline hydrochloride (EVP-6124), is currently being evaluated in separate ongoing Phase 3 clinical trial programs: COGNITIV SZ, which looks to improve cognitive impairment in patients with schizophrenia, and COGNITIV AD, which aims to improve cognition in patients with Alzheimer’s disease. Privately owned, FORUM Pharmaceuticals is based in Watertown, Mass. For more information about FORUM, visit www.forumpharma.com.
FORUM Pharmaceuticals and the FORUM octagon logo are trademarks of FORUM Pharmaceuticals Inc..
Help employers find you! Check out all the jobs and post your resume.
comments powered by